G
Guido Kroemer
Researcher at Institut Gustave Roussy
Publications - 1546
Citations - 294816
Guido Kroemer is an academic researcher from Institut Gustave Roussy. The author has contributed to research in topics: Programmed cell death & Apoptosis. The author has an hindex of 236, co-authored 1404 publications receiving 246571 citations. Previous affiliations of Guido Kroemer include Karolinska Institutet & Spanish National Research Council.
Papers
More filters
Journal ArticleDOI
Chaperone-mediated autophagy degrades mutant p53
Helin Vakifahmetoglu-Norberg,Minsu Kim,Hongguang Xia,Marcin P. Iwanicki,Dimitry Ofengeim,Jonathan L. Coloff,Lifeng Pan,Tan A. Ince,Guido Kroemer,Joan S. Brugge,Junying Yuan +10 more
TL;DR: This work shows that suppression of macroautophagy by multiple means promotes the degradation of mutant p53 through chaperone-mediated autophagy in a lysosome-dependent fashion, and delineates a novel strategy for killing tumor cells that depend on Mutant p53 expression by the activation of chaper one-mediatedAutophagy.
Journal ArticleDOI
eIF2α phosphorylation is pathognomonic for immunogenic cell death.
Lucillia Bezu,Allan Sauvat,Juliette Humeau,Lígia C. Gomes-da-Silva,Kristina Iribarren,Sabrina Forveille,Pauline Garcia,Liwei Zhao,Peng Liu,Laurence Zitvogel,Laurence Zitvogel,Laura Senovilla,Oliver Kepp,Guido Kroemer +13 more
TL;DR: Machine-learning approaches were used to determine the physicochemical properties of drugs that induce ICD, revealing that the sole ER stress response relevant to the algorithm is eIF2α phosphorylation with its downstream consequences CALR exposure, stress granule formation and autophagy induction.
Journal ArticleDOI
Trial Watch: Toll-like receptor agonists for cancer therapy.
Erika Vacchelli,Alexander M.M. Eggermont,Catherine Sautès-Fridman,Jérôme Galon,Laurence Zitvogel,Guido Kroemer,Lorenzo Galluzzi +6 more
TL;DR: The latest developments in this exciting area of research are summarized, focusing on preclinical studies that have been published during the last 13 mo and clinical trials launched in the same period to investigate the antineoplastic activity of TLR agonists.
Journal ArticleDOI
Unsaturated fatty acids induce non‐canonical autophagy
Mireia Niso-Santano,Mireia Niso-Santano,Shoaib Ahmad Malik,Federico Pietrocola,José Manuel Bravo-San Pedro,José Manuel Bravo-San Pedro,Guillermo Mariño,Guillermo Mariño,Valentina Cianfanelli,Amena BenYounès,Amena BenYounès,Rodrigo Troncoso,Maria Markaki,Valentina Sica,V. Izzo,V. Izzo,Kariman Chaba,Chantal Bauvy,Chantal Bauvy,Nicolas Dupont,Nicolas Dupont,Oliver Kepp,Oliver Kepp,Patrick Rockenfeller,Heimo Wolinski,Frank Madeo,Sergio Lavandero,Patrice Codogno,Patrice Codogno,Francis Harper,Francis Harper,Gérard Pierron,Gérard Pierron,Nektarios Tavernarakis,Nektarios Tavernarakis,Francesco Cecconi,Maria Chiara Maiuri,Maria Chiara Maiuri,Lorenzo Galluzzi,Guido Kroemer +39 more
TL;DR: Unsaturated fatty acids induce a non‐canonical, phylogenetically conserved, autophagic response that in mammalian cells relies on the Golgi apparatus, and downregulation of BECN1 and PIK3C3 abolished palmitate‐ induced, but not oleate‐induced, Autophagy in human cancer cells.
Journal ArticleDOI
Trial watch: TLR3 agonists in cancer therapy.
Julie Le Naour,Lorenzo Galluzzi,Laurence Zitvogel,Laurence Zitvogel,Guido Kroemer,Erika Vacchelli,Erika Vacchelli +6 more
TL;DR: Recent preclinical and clinical advances in the development of TLR3 agonists for oncological disorders are reviewed.